Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

NCT02909036 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Amyloidosis

Interventions

DEVICE: Melphalan
DRUG: Pegfilgrastim
PROCEDURE: Autologous Hematopoietic Progenitor Cell Transplant

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]